ReviewDiagnostics (Basel, Switzerland)2024
Presepsin in Critical Illness: Current Knowledge and Future Perspectives.
Review in Diagnostics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic accuracy of presepsin for sepsis in adult patients according to the criteria of sepsis-3: systematic review and meta-analysis.BMC anesthesiology · 2026Pooled it
- A Prediction Score Versus Procalcitonin and Presepsin for Predicting Bacteremia in the Emergency Department: A Single-Center Retrospective Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- Presepsin Outperforms Conventional Inflammatory Markers in Distinguishing Malignant from Benign Cervical Lymphadenopathy.Journal of clinical medicine · 2026Article
- Severity and 28-day in-hospital mortality of interleukin-6, neutrophil to lymphocyte ratio, and APACHE II score in patients with sepsis.Frontiers in cellular and infection microbiology · 2026Article
- Biomarker-based diagnosis of ventilator-associated pneumonia using serum and bronchoalveolar lavage fluid levels of presepsin, procalcitonin, and lipopolysaccharide-binding protein.Frontiers in cellular and infection microbiology · 2026Article
- Narrative Review: Research Progress and Future Directions of Presepsin in Neurological Prognostication of Adult Post-Return of Spontaneous Circulation (Post-ROSC) Cardiac Arrest Survivors.Journal of inflammation research · 2026Review
- Early Sepsis Detection in Adult Patients with Suspected Sepsis in an Emergency Setting: A Sequential Strategy of Monocyte Distribution Width and Presepsin.Diagnostics (Basel, Switzerland) · 2025Article
- Presepsin as a Diagnostic and Prognostic Biomarker of Sepsis-Associated Acute Kidney Injury: A Scoping Review of Clinical Evidence.Journal of clinical medicine · 2025Review
- Diagnostic Accuracy of Presepsin and Its Impact on Early Antibiotic De-Escalation in Burn-Related Sepsis.Antibiotics (Basel, Switzerland) · 2025Article
- Presepsin in Hepatic Pathology: Bridging the Gap in Early Sepsis Detection.Diagnostics (Basel, Switzerland) · 2025Review
- The potential role of leukocytes cell population data (CPD) for diagnosing sepsis in adult patients admitted to the intensive care unit.Clinical chemistry and laboratory medicine · 2025Observational
- Globotriaosylceramide as a potential biomarker for auxiliary detection of lower respiratory tract infections ofExperimental and therapeutic medicine · 2025Article
- Elevated Serum Presepsin Identifies Herpes Simplex Virus-1 Reactivation in COVID-19 Patients.Viruses · 2025Article
- Biomarker Insights: Evaluation of Presepsin, Apelin, and Irisin Levels in Cutaneous Leishmaniasis.Diagnostics (Basel, Switzerland) · 2024Article
- Combining PCT with CRP is better than separate testing for patients with bacteriuria in the intensive care unit: a retrospective study.European journal of medical research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The accurate identification of infections is critical for effective treatment in intensive care units (ICUs), yet current diagnostic methods face limitations in sensitivity and specificity, alongside cost and accessibility issues. Consequently, there is a pressing need for a marker that is economically feasible, rapid, and reliable. Presepsin (PSP), also known as soluble CD14 subtype (sCD14-ST), has emerged as a promising biomarker for early sepsis diagnosis. PSP, derived from soluble CD14, reflects the activation of monocytes/macrophages in response to bacterial infections. It has shown potential as a marker of cellular immune response activation against pathogens, with plasma concentrations increasing during bacterial infections and decreasing post-antibiotic treatment. Unlike traditional markers such as procalcitonin (PCT) and C-reactive protein (CRP), PSP specifically indicates monocyte/macrophage activation. Limited studies in critical illness have explored PSP's role in sepsis, and its diagnostic accuracy varies with threshold values, impacting sensitivity and specificity. Recent meta-analyses suggest PSP's diagnostic potential for sepsis, yet its standalone effectiveness in ICU infection management remains uncertain. This review provides a comprehensive overview of PSP's utility in ICU settings, including its diagnostic accuracy, prognostic value, therapeutic implications, challenges, and future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.